N-(4-(4-(6-(6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)pyridin-3-yl)piperazin-1-yl)butyl)-2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-ylamino)acetamide

ID: ALA4646450

PubChem CID: 132020044

Max Phase: Preclinical

Molecular Formula: C43H49N11O7

Molecular Weight: 831.94

Molecule Type: Unknown

This compound is available for customization.

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCN(CCCCNC(=O)CNc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)CC4)cn3)nc2n(C2CCCC2)c1=O

Standard InChI: InChI=1S/C43H49N11O7/c1-25-30-23-47-43(50-38(30)53(27-8-3-4-9-27)41(60)36(25)26(2)55)48-33-14-12-28(22-46-33)52-20-18-51(19-21-52)17-6-5-16-44-35(57)24-45-31-11-7-10-29-37(31)42(61)54(40(29)59)32-13-15-34(56)49-39(32)58/h7,10-12,14,22-23,27,32,45H,3-6,8-9,13,15-21,24H2,1-2H3,(H,44,57)(H,49,56,58)(H,46,47,48,50)

Standard InChI Key: AWPNCYPNCSCZFL-UHFFFAOYSA-N

Molfile:

 
     RDKit          2D

 61 68  0  0  0  0  0  0  0  0999 V2000
   29.7892   -6.1718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.7892   -6.9999    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.5045   -7.4119    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.5045   -5.7556    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.2198   -6.1718    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.2182   -6.9981    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.9325   -7.4129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.6488   -6.9984    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   32.6464   -6.1689    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.9316   -5.7620    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   30.5013   -4.9298    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.1720   -4.4413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.9173   -3.6534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.0891   -3.6534    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.8304   -4.4413    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.3629   -5.7546    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.0779   -6.1644    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.0755   -6.9927    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.7938   -7.4065    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.5112   -6.9880    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.5060   -6.1555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.7871   -5.7497    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.2269   -7.3993    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.2286   -8.2285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9442   -8.6372    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.6625   -8.2254    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   37.6608   -7.3963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9406   -6.9788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   30.5057   -8.2401    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0702   -5.7619    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   29.0720   -7.4171    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   28.3536   -7.0020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   29.0731   -8.2453    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   38.3759   -8.6378    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.0897   -8.2262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   39.8032   -8.6385    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   40.5170   -8.2269    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.2304   -8.6392    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   41.9442   -8.2276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   42.6576   -8.6400    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   41.9446   -7.4036    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   43.3714   -8.2283    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   44.0848   -8.6407    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.0813   -9.4647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.7938   -9.8770    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.5086   -9.4653    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.7933   -8.2285    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.5046   -8.6340    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   46.1101   -8.0829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.7730   -7.3366    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   44.9593   -7.4267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   44.4046   -6.8173    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   46.9170   -8.2499    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   46.1812   -6.6208    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   45.7652   -5.9094    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   46.1734   -5.1936    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   44.9413   -5.9139    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   46.9974   -5.1891    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   47.4055   -4.4733    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   47.4133   -5.9005    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   47.0052   -6.6163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  1  4  1  0
  2  3  2  0
  3  6  1  0
  5  4  1  0
  5  6  2  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
 11 12  1  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 11  1  0
  4 11  1  0
  9 16  1  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 21  1  0
 21 22  2  0
 22 17  1  0
 23 24  1  0
 23 28  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 28  1  0
 20 23  1  0
  3 29  1  0
  1 30  2  0
  2 31  1  0
 31 32  1  0
 31 33  2  0
 26 34  1  0
 34 35  1  0
 35 36  1  0
 36 37  1  0
 37 38  1  0
 38 39  1  0
 39 40  1  0
 39 41  2  0
 40 42  1  0
 42 43  1  0
 43 44  2  0
 44 45  1  0
 45 46  2  0
 46 48  1  0
 47 43  1  0
 47 48  2  0
 48 49  1  0
 49 50  1  0
 50 51  1  0
 51 47  1  0
 51 52  2  0
 49 53  2  0
 50 54  1  0
 54 61  1  0
 54 55  1  0
 55 56  1  0
 55 57  2  0
 56 58  1  0
 58 59  2  0
 58 60  1  0
 60 61  1  0
M  END

Associated Targets(Human)

CDK4 Tclin Cyclin-dependent kinase 4/cyclin D1 (2340 Activities)

Discover Target: CDK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CCND3 Tchem CDK6/cyclin D3 (897 Activities)

Discover Target: CCND3

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK4 Tclin Protein cereblon/Cyclin-dependent kinase 4 (68 Activities)

Discover Target: CDK4

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

CDK6 Tclin Protein cereblon/Cyclin-dependent kinase 6 (113 Activities)

Discover Target: CDK6

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type: Unknown	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 831.94	Molecular Weight (Monoisotopic): 831.3816	AlogP: 3.09	#Rotatable Bonds: 14
Polar Surface Area: 220.93	Molecular Species: NEUTRAL	HBA: 15	HBD: 4
#RO5 Violations: 2	HBA (Lipinski): 18	HBD (Lipinski): 4	#RO5 Violations (Lipinski): 2
CX Acidic pKa: 11.14	CX Basic pKa: 8.01	CX LogP: 2.59	CX LogD: 1.89
Aromatic Rings: 4	Heavy Atoms: 61	QED Weighted: 0.08	Np Likeness Score: -1.11

References

1. Anderson NA, Cryan J, Ahmed A, Dai H, McGonagle GA, Rozier C, Benowitz AB.. (2020) Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs., 30 (9): [PMID:32184044] [10.1016/j.bmcl.2020.127106]
2. Zeng S, Huang W, Zheng X, Liyan Cheng, Zhang Z, Wang J, Shen Z.. (2021) Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges., 210 [PMID:33160761] [10.1016/j.ejmech.2020.112981]
3. Gray, N S NS and 12 more authors. 1998-07-24 Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. [PMID:9677190]
4. Kubo, A A and 9 more authors. 1999-12 The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4. [PMID:10632371]
5. Soni, R R and 7 more authors. 2000-09-07 Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. [PMID:10973815]
6. Lane, M E ME and 9 more authors. 2001-08-15 A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. [PMID:11507069]
7. Tavares, Francis X FX and 7 more authors. 2004-09-09 N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy. [PMID:15341487]
8. Fry, David W DW and 10 more authors. 2004-11 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. [PMID:15542782]
9. Pennati, Marzia M and 12 more authors. 2005-09 Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. [PMID:16170024]
10. Sridhar, Jayalakshmi J, Akula, Nagaraju N and Pattabiraman, Nagarajan N. 2006-03-24 Selectivity and potency of cyclin-dependent kinase inhibitors. [PMID:16584130]
11. DePinto, Wanda W and 19 more authors. 2006-11 In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. [PMID:17121911]
12. Joshi, Kalpana S KS and 7 more authors. 2007-03 In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00. [PMID:17363486]
13. Squires, Matthew S MS and 7 more authors. 2009-02 Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. [PMID:19174555]
14. Cirstea, D D and 15 more authors. 2013-12 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. [PMID:23807770]
15. Gelbert, Lawrence M LM and 16 more authors. 2014-10 Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. [PMID:24919854]
16. Paiva, Cody C and 8 more authors. 2015 Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. [PMID:26606677]
17. Bisi, John E JE, Sorrentino, Jessica A JA, Roberts, Patrick J PJ, Tavares, Francis X FX and Strum, Jay C JC. 2016-05 Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. [PMID:26826116]
18. Klaeger, Susan S and 47 more authors. 2017-12-01 The target landscape of clinical kinase drugs. [PMID:29191878]
19. Wang, Yan Y and 10 more authors. 2018-03-01 Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships. [PMID:29429832]
20. Tear, Westley F and 16 more authors. 2020-01-23 Selectivity and Physicochemical Optimization of Repurposed Pyrazolo[1,5-b]pyridazines for the Treatment of Human African Trypanosomiasis. [PMID:31846577]
21. Wu, Tizhi and 6 more authors. 2020-11-25 Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update. [PMID:32866383]

N-(4-(4-(6-(6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)pyridin-3-yl)piperazin-1-yl)butyl)-2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-ylamino)acetamide

Names and Identifiers

Alternative Forms

Associated Targets(Human)

Molecule Features

Drug Indications

Mechanisms of Action

Biocomponents

Calculated Properties

References

Source